Markets

Nuvectis Pharma's NXP200 BRAF Inhibitor Receives China's Breakthrough Therapy Designation

Sep 24, 2026 · 08:05 AM ET· updated 1h ago

Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related

Why It Matters

Nuvectis got official recognition from China for a new cancer medicine. This shows the drug might work and could reach patients faster there.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

NVCT21.18

+0.11 (+0.54%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.